Technology Feasibility Assessment for Viral Nervous Necrosis Prevention and Management
A leading biotechnology firm engaged Stellarix for competitive benchmarking and technology feasibility assessment. Our strategic insights helped the client accelerate market readiness by identifying gaps and pinpointing scalable innovations in aquaculture, specifically supporting the development of commercial vaccines for VNN (Viral Nervous Necrosis). Client Background: A Global life sciences and biotechnology conglomerate specializing in sustainable […]
Market Assessment and Capacity Planning for Pancreatic Cancer CDMO Entry
A global Contract Development and Manufacturing Organization (CDMO) sought Stellarix’s support to assess the strategic and financial viability of pancreatic cancer-focused manufacturing devices. Our strategic intelligence enabled demand-driven capacity planning and informed market entry through effective risk mitigation and clear market visibility. Client Background: A global Contract Development and Manufacturing Organization (CDMO) intended to evaluate […]
Innovation and Partnership Scouting for Neonatology Portfolio Expansion
A world-leading biopharmaceutical company sought to expand its neonatology portfolio through strategic partnerships and early-stage technology adoption. Our strategic intelligence enabled the client to prioritize their partnership opportunities and confidently expand their portfolio. Client Background: A global, research-driven biopharmaceutical organization with a strong focus on innovation in respiratory health, rare diseases, and specialty care was […]
Will Next-Gen Neurotherapeutics Render Legacy Antidepressant Models Obsolete?
For the last three decades, Selective Serotonin Reuptake Inhibitors (SSRIs) have been the highlight of psychiatric pharmacology. However, their commercial supremacy rests on a precarious foundation – their broad-spectrum efficacy contradicts the deeply heterogeneous population of patients. This sector is now confronting an “efficacy ceiling” due to stagnating pipelines of SSRI drugs and patent cliffs […]
Improving Competitiveness of a Biopharma Leader through Psilocybin Landscape Mapping
A global biopharma leader engaged us to conduct a comprehensive therapeutic landscape assessment to expand its innovation portfolio with next-generation therapies for treatment-resistant neurological disorders. Stellarix helped the client sharpen its competitive position and innovation edge through an improved portfolio strategy and faster, data-driven decision-making. Client Background: A global biopharmaceutical company focused on central nervous […]
Mental Health Innovation: Why Psychedelic Therapies are Attracting Big Pharma?
Psychedelic therapies are witnessing an exponential surge in the mental health space. This resurgence stems from simplified or relaxed regulatory barriers, shifts in public perception, and the lack of new psychopharmacological options in the psychiatry pipeline. Additionally, rigorous scientific research on psychedelic drugs and evidence of efficacy from clinical trials are also adding to their […]
Redefining Psychiatry: Psychedelic Neurotherapeutics as a Clinical Paradigm Shift
What’s Driving the Renewed Interest in Psychedelic Medicine? The increasing acceptance of psychedelic neuro-therapeutics is changing mental health care while eliminating harm for the most difficult-to-treat malaise of our times: anxiety, depression, addiction, PTSD, etc. Encouraging early results with psychedelics like psilocybin, MDMA, and others have spurred the opening of clinics offering them, and will […]
Advanced Therapeutics Hub: Strategic Intelligence for Next-Generation Biopharma
Executive Summary: The Frontier of Next-Generation Medicines The worldwide healthcare and life science industry is changing its structure fundamentally. Traditional small-molecule drugs and standard biologics are being supplemented and, in some instances, replaced by advanced therapeutics that mend the damage at genetic, cellular, and molecular levels. The transformation to the future of healthcare is largely […]
Endosomal Escape: Unlocking Critical Hurdles of Intracellular Delivery
How Endosomal Escape Determines Success in Modern Medicine The “Endosomal trap” is responsible for eliminating 90–99% of the administered vaccine dose, resulting in low therapeutic potency, dose inefficiency, and limited clinical translation. When nanoparticles, viral vectors, and lipid carriers are taken into membrane-bound endosomes, these are sent to lysosomal degradation if the therapeutic cargo does […]
Technology Overview & Start-up Scouting for Development of Allogeneic iPSCs
A clinical-stage biopharmaceutical company approached Stellarix to get a technology and innovation overview in the allogeneic iPSCs segment. Our strategic intelligence helped the client gain a future outlook on allogeneic iPSCs development with HLA/MHC knockdown, reforming its market and business strategy. Client Background: Clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent […]